A Pilot Study of Immune Activation and Rifampin Absorption in HIV-Infected Patients without Tuberculosis Infection: A Short Report

Table 1

Immune activation, intestinal assays, and rifampin PK measures.

Characteristic	Study participant ID						Median value
	101	102	103	104	105	106
Demographics
Age (years)	27	25	27	22	33	29	27
Weight (kg)	90	65	117	62	90	84	87
Sex	F	M	M	M	M	M	—
Immunologic measures
CD4+ T cells (per uL)	1573	367	416	724	626	843	675
sCD14 (ng/mL)	2412	1260	1438	1435	954	1243	1347.5
%CD38+			0	0.2	0.3	0.3	0.3
%HLA-DR+			21.7	9.6	16.2	28.7	19.0
%CD57+			7.5	2.1	0.7	10.8	4.8
%CD38+			1.6	0.5	1.8	4.7	1.7
%HLA-DR+			73.1	27.1	81.7	73.0	73.1
%CD57+			37.2	11.3	16.1	5.8	13.7
Intestinal assays
D-Xylose excretion in urine (g, normal > 4.4 g)	4.6	4.4	4.4	3.3	5.0	5.7	4.5 g
Lactulose/mannitol ratio	0.09	0.11	0.08	0.04	0.05	0.06	0.07
Rifampin PK measures
(mghr/L)	28.1	43.1	21.2	57.6	46.6	42.4	42.8
(mg/L)	7.8	11.6	5.3	12.5	12.5	8.7	10.1
(hours)	4	1.5	2.5	1.5	1	1	1.5
Clearance (L/hr)	10.3	7.2	15.9	7.6	8.1	7.8	8.0
Volume of distribution (L)	76.9	51.7	113.2	48.0	48.0	69.0	60.4

Insufficient number of PBMCs for flow cytometry.